Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Share News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 66.50
Bid: 65.00
Ask: 68.00
Change: 0.00 (0.00%)
Spread: 3.00 (4.615%)
Open: 66.50
High: 66.50
Low: 66.50
Prev. Close: 66.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens

Thu, 28th Sep 2023 14:24

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Dar Global PLC - luxury international real estate developer - In the six months that ended June 30, pretax profit multiplies to GBP20.8 million from GBP3.7 million a year earlier. Revenue also multiplies to GBP108.4 million from GBP27.5 million. Chief Executive Officer Ziad El Chaar says: "2023 has been a milestone year for the company with our successful listing on the London Stock Exchange in February representing a significant step forward in supporting our ambitious growth trajectory. The second half has started strongly and we are well positioned to weather some of the challenges facing the sector through the strength of our balance sheet, building partnerships with other global luxury brands and further expanding our pipeline of opportunities."

----------

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - In the six months that ended June 30, pretax loss widens to GBP4.3 million from GBP1.1 million. Posts no revenue, unchanged, while administrative expenses widen to GBP3.9 million from GBP1.1 million. Chief Executive Officer Vladislav Sandler says: "While the placing of Hemo-Car-T on clinical hold was a setback, we are clear on the particular area in which additional information is required, and we are encouraged by the [US Food & Drug Administration]'s response to our plans to resolve the issues. We remain confident and committed to progressing Hemo-Car-T to clinical trials as the company's next step. We have put measures in place to allow us to achieve this milestone, including the new agreement with Prevail InfoWorks and the investment by Prevail Partners, which gives a clear signal of the project's value even at this pre-clinical phase. Meanwhile, the prospects for our other cutting-edge assets continue to be positive, and CBR in particular is beginning to attract real attention."

----------

Lansdowne Oil & Gas PLC - North Celtic Sea-focused oil and gas company - In the six months that ended June 30, pretax loss widens to GBP16.1 million from GBP158,000 a year earlier. This is due to a one-off impairment of intangible assets of GBP15.9 million. Says it remains confident of amicable resolution with Ireland over Barryroe oil field, after receiving a letter in May from the Irish Department of the Environment, Climate & Communications, advising that the minister would not grant the lease undertaking, as sought, on grounds of financial capability. Says: "We continue to maintain that the failure to allow the Barryroe oil and gas field to progress to development is against the best interests of Ireland."

----------

Metals One PLC - London-based mining company, which is focused on battery metals projects in Finland and Norway - In the six months that ended June 30, pretax loss narrows to GBP118,893 from GBP154,371 a year earlier, as administrative expenses narrow to GBP118,893 from GBP184,017. Chair Alastair Clayton says: "The six-month period...was incredibly busy for the company as it worked towards completion of its [initial public offering] and concurrent acquisitions of European brownfield battery metals projects which occurred after the reporting period. With European brownfield projects, experienced partners, and funded work programmes in place, our projects are well positioned for rapid advancement as we seek to establish ethically mined sources of critical minerals, including nickel, in Europe, close to future customers. Exploration in Norway is well underway with Kingsrose, whilst in Finland we are finalising plans to commence phase one drilling in the near future. We look forward to updating shareholders on further news as we continue our work programmes."

----------

NetScientific PLC - London-based investment firm focused on life science, sustainability and technology companies - In the six months that ended June 30, pretax loss narrows to GBP1.6 million from GBP1.7 million a year earlier. Total income during the period was up to GBP1.2 million from GBP656,000 a year earlier, with revenue up to GBP770,000 from GBP391,000. Chief Executive Officer Ilian Iliev says: "During the first half of 2023 we have made significant progress and achieved important milestones as we continue to successfully execute on our 'evergreen' strategy, covering core operating costs through a combination of corporate finance fees and value creation services fees via our wholly owned subsidiary, EMV Capital. We have also demonstrated our ability to generate profitable partial exits from our portfolio, even in the absence of a strong [mergers & acquisitions] or [initial public offering] market. This essential funding for our portfolio companies has helped to facilitate the execution of their growth strategies and preparations for forthcoming scale-up investment rounds as well as supporting the appreciating fair value of NetScientific's direct holdings. In such a challenging venture capital landscape, characterised by macroeconomic volatility and industry fluctuations, our in-house fundraising capacity distinguishes us from many of our peers."

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 May 2015 08:24

NetScientific Forms New Sales Subsidiary With Meridian Health

Read more
24 Mar 2015 11:25

NetScientific Posts Widened Loss As Portfolio Companies Ramp Up

Read more
16 Jan 2015 18:27

NetScientific CEO "Removed" After Board "Unanimously Agreed To Terminate" Contract

Read more
3 Oct 2014 06:53

NetScientific Inks Deal With Oncimmune For Liver Cancer Detection

Read more
23 Sep 2014 11:57

NetScientific Posts Widened Loss On Higher Research Costs

Read more
23 Jul 2014 09:40

NetScientific Makes Investments In G-Tech Medical, Longevity Biotech

Read more
2 Jul 2014 09:01

NetScientific US Division Secures DNA Sequencing Research Programme

Read more
9 Jun 2014 16:07

NetScientific Enters New Service Agreement With Director

LONDON (Alliance News) - NetScientific PLC Monday said it has entered into a new service agreement with Peter Thoms, a director of the company. The biomedical and healthcare technology investment company said the agreement is terminable on six months notice by either party. NetScienti

Read more
20 May 2014 12:24

NetScientific Confident For Full-Year On Strong Pipeline, Early Trading

LONDON (Alliance News) - NetScientific PLC said Tuesday it is confident for its full-year outlook, supported by a strong pipeline and as trading for the year has started well. In a statement released ahead of its annual general meeting Tuesday, Chairman Sir Richard Sykes said that the firm

Read more
19 May 2014 10:45

NetScientific Firm Signs Research Agreement with Harvard University

LONDON (Alliance News) - NetScientific PLC said Monday its Palo Alto-based subsidiary, Vortex Biosciences Inc, has signed a research agreement with the Rowland Institute at Harvard University. The biomedical and healthcare technology investment group said that under the research agreement,

Read more
26 Mar 2014 13:29

NetScientific forms strategic alliance with start-up investor

AIM-listed NetScientific, a biomedical and healthcare technology investment group, has formed a strategic alliance with San Francisco-based Breakout Labs, it announced Wednesday. Under the agreement NetScientific will invest up to $0.25m in Breakout Labs portfolio companies that fit its investment

Read more
26 Mar 2014 13:22

Netscientific To Invest In Medical Tech Firms Via Peter Thiel Fund

LONDON (Alliance News) - Netscientific PLC said Wednesday that it had entered a strategic alliance with PayPal co-founder Peter Thiel's fund Breakout Labs, which is based in San Francisco, to invest USD250,000 in medical technologies companies. The fund supports early-stage companies that a

Read more
19 Mar 2014 12:57

NetScientific Widens Pretax Loss On Listing Costs, Reorganisation

LONDON (Alliance News) - NetScientific PLC Wednesday expressed confidence for further progress with its portfolio companies in 2014, as its pretax loss widened in 2013 due costs arising from its AIM listing and restructuring. The biomedical and healthcare technology investment group raised

Read more
24 Feb 2014 10:40

NetScientific Takes Majority Stake In Diagnostic Tests Firm ProAxsis

LONDON (Alliance News) - NetScientific PLC said Monday that it had made an investment in Queen's University Belfast's spin-out company ProAxsis Ltd. The company said it will take a majority stake alongside existing investor Queen's University Spin Out Vehicle. It did not provide financial d

Read more
30 Sep 2013 12:37

DIRECTOR DEALINGS: NetScientific Non-Exec Director Purchases Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.